Wong et al. demonstrated a significant reduction in lung cancer incidence and mortality by employing the IL-1B inhibitor canasumab to target inflammatory cells and inhibit the IL-1B inflammatory pathway [9]. This evidence concerns the gene IL1B and lung carcinoma.